Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01027013 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
A Phase 2 study of Dry Eye Syndromes and Keratoconjunctivitis Sicca, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 5
- Study locations
NCT01027013: Completed Phase 2 study of Dry Eye Syndromes and Keratoconjunctivitis Sicca, sponsored by Kubota Vision.
NCT01027013 is a Phase 2 study of Dry Eye Syndromes and Keratoconjunctivitis Sicca that has completed, run by Kubota Vision. The registered enrollment target is 220 participants, below the 401-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (45% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01027013, a Phase 2 study of Dry Eye Syndromes and Keratoconjunctivitis Sicca, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of rebamipide 2% suspension for the treatment of patients with dry-eye.
Conditions Studied
Interventions
- DRUG rebamipide 2% ophthalmic suspension
- DRUG placebo eye drops
Study Locations (5)
Connecticut
- The Eye Care Group, P.C. - Waterbury
Kentucky
- Richard Eiferman, MD - Louisville
Maine
- Central Maine Eye Care - Lewiston
Massachusetts
- Ora, Inc - Andover
Tennessee
- Total Eye Care, P.A. - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT01027013 record still lists
NCT01027013 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 401-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (45% lower).
The record links to 2 conditions, with Dry Eye Syndromes appearing as the primary indexed condition, and to 2 interventions - of which rebamipide 2% ophthalmic suspension is the first listed.
NCT01027013 lists 5 locations in 5 states (Connecticut, Kentucky, Maine).
Frequently Asked Questions
What is clinical trial NCT01027013 about?
NCT01027013 is a clinical study titled "Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye". The purpose of this study is to evaluate the safety and efficacy of rebamipide 2% suspension for the treatment of patients with dry-eye.
What is the current status of trial NCT01027013?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2009-12. Estimated completion is 2010-11.
What conditions does trial NCT01027013 study?
This clinical trial studies the following conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca.
What interventions are being tested in trial NCT01027013?
The interventions under investigation include: rebamipide 2% ophthalmic suspension (DRUG), placebo eye drops (DRUG).
Who is sponsoring clinical trial NCT01027013?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01027013 being conducted?
This trial has 5 study locations across Connecticut, Kentucky, Maine, Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01027013's enrollment target sits among peer trials
220 5th of 17 higher than 13 of 17 other Dry Eye Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye
COMPLETED · Phase 2
-
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
COMPLETED · Phase 2
-
Dry Eye Assessment and Management: Feasibility Study
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.
COMPLETED · Phase 2
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia